<DOC>
	<DOC>NCT02267733</DOC>
	<brief_summary>A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status</brief_summary>
	<brief_title>Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients</brief_title>
	<detailed_description>In this study, we will administer FluzoneÂ® High-Dose vaccine with a planned booster to patients with monoclonal gammopathies (stratified by requirement for therapy) irrespective of age. All patients will receive an initial vaccine followed by a booster vaccine 30 days (+/- 7 days) later and will then be followed for outcomes until the end of flu season.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Understand and voluntarily sign an informed consent document Age &gt;= 18 years at the time of signing the informed consent form Diagnosis of any monoclonal gammopathy; Monoclonal Gammopathy of Undetermined Significance (MGUS), asymptomatic/ active multiple myeloma, asymptomatic / active Waldenstrom Macroglobulinemia (WM) An serious egg allergy or prior serious adverse reaction to an influenza vaccine Use of any other influenza vaccine for the 2014 to 2015 flu season Women who are pregnant or plan to become pregnant in the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>